CA2268450C - Neurotrophin antagonist compositions - Google Patents
Neurotrophin antagonist compositions Download PDFInfo
- Publication number
- CA2268450C CA2268450C CA002268450A CA2268450A CA2268450C CA 2268450 C CA2268450 C CA 2268450C CA 002268450 A CA002268450 A CA 002268450A CA 2268450 A CA2268450 A CA 2268450A CA 2268450 C CA2268450 C CA 2268450C
- Authority
- CA
- Canada
- Prior art keywords
- isoquinoline
- dioxo
- tetrahydrobenzo
- nitro
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/14—Aza-phenalenes, e.g. 1,8-naphthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9621902.7A GB9621902D0 (en) | 1996-10-21 | 1996-10-21 | Neurotrophin antagonist compositions |
| GB9621902.7 | 1996-10-21 | ||
| GB9710904.5 | 1997-05-27 | ||
| GBGB9710904.5A GB9710904D0 (en) | 1997-05-27 | 1997-05-27 | Neurotropin antagonist compositions |
| PCT/CA1997/000779 WO1998017278A1 (en) | 1996-10-21 | 1997-10-20 | Neurotrophin antagonist compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2268450A1 CA2268450A1 (en) | 1998-04-30 |
| CA2268450C true CA2268450C (en) | 2008-08-05 |
Family
ID=26310264
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002268450A Expired - Fee Related CA2268450C (en) | 1996-10-21 | 1997-10-20 | Neurotrophin antagonist compositions |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US20020169182A1 (enExample) |
| EP (1) | EP0930883B1 (enExample) |
| JP (1) | JP2001503397A (enExample) |
| KR (1) | KR20000052691A (enExample) |
| AT (1) | ATE315397T1 (enExample) |
| AU (1) | AU728523C (enExample) |
| BR (1) | BR9712424A (enExample) |
| CA (1) | CA2268450C (enExample) |
| DE (1) | DE69735090T2 (enExample) |
| DK (1) | DK0930883T3 (enExample) |
| ES (1) | ES2257768T3 (enExample) |
| IL (1) | IL129475A0 (enExample) |
| NZ (1) | NZ335291A (enExample) |
| WO (1) | WO1998017278A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU728523C (en) | 1996-10-21 | 2001-08-09 | Nps Pharmaceuticals, Inc. | Neurotrophin antagonist compositions |
| CN1328549A (zh) * | 1998-11-25 | 2001-12-26 | 默克专利股份公司 | 取代苯并[de]异喹啉－1,3－二酮类化合物 |
| AU760136B2 (en) * | 1998-11-25 | 2003-05-08 | Merck Patent Gmbh | Substituted benzo(DE)isoquinoline-1,3-diones |
| US6468990B1 (en) * | 1999-05-17 | 2002-10-22 | Queen's University At Kingston | Method of inhibiting binding of nerve growth factor to p75 NTR receptor |
| US6492380B1 (en) | 1999-05-17 | 2002-12-10 | Queen's University At Kingston | Method of inhibiting neurotrophin-receptor binding |
| FR2807660A1 (fr) * | 2000-04-13 | 2001-10-19 | Warner Lambert Co | Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques |
| US7255860B2 (en) | 2002-10-08 | 2007-08-14 | Rinat Neuroscience Corp. | Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody |
| WO2004032870A2 (en) | 2002-10-08 | 2004-04-22 | Rinat Neuroscience Corp. | Methods for treating post-surgical pain by admisnistering a nerve growth factor antagonist and compositions containing the same |
| UA80447C2 (en) | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
| US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
| US9498530B2 (en) | 2002-12-24 | 2016-11-22 | Rinat Neuroscience Corp. | Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same |
| DK1575517T3 (da) | 2002-12-24 | 2012-05-14 | Rinat Neuroscience Corp | Anti-ngf-antistoffer og fremgangsmåder til anvendelse af samme |
| KR20050111598A (ko) | 2003-02-19 | 2005-11-25 | 리나트 뉴로사이언스 코퍼레이션 | 신경 성장 인자 길항제 및 ｎｓａｉｄ를 투여함으로써통증을 치료하는 방법 및 그것을 함유하는 조성물 |
| FR2862968B1 (fr) * | 2003-12-01 | 2006-08-04 | Sanofi Synthelabo | Derives de 4-[(arylmethyl)aminomethyl]piperidine, leur preparation et leur application en therapeutique |
| FR2862967B1 (fr) * | 2003-12-01 | 2006-08-04 | Sanofi Synthelabo | Derives de (4-phenylpiperazin-1-yl)acylpiperidine, leur preparation et leur application en therapeutique |
| KR101637908B1 (ko) | 2004-04-07 | 2016-07-11 | 리나트 뉴로사이언스 코프. | 신경성장인자 길항제의 투여에 의한 골암 통증의 치료방법 |
| GB0419850D0 (en) * | 2004-09-07 | 2004-10-13 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| US20070099900A1 (en) * | 2005-09-15 | 2007-05-03 | Painceptor Pharma Corporation | Methods of modulating neurotrophin-mediated activity |
| WO2009039635A1 (en) * | 2007-09-24 | 2009-04-02 | Painceptor Pharma Corporation | Methods of modulating neurotrophin-mediated activity |
| FR2953839A1 (fr) | 2009-12-14 | 2011-06-17 | Sanofi Aventis | Nouveaux derives d'(heterocycle-piperidine condensee)-(piperazinyl)-1alcanone ou d'(heterocycle-pyrrolidine condensee)-(piperazinyl)-1alcanone et leur utilisation comme inhibiteurs de p75 |
| ES2665954T3 (es) | 2010-08-19 | 2018-04-30 | Zoetis Belgium S.A. | Anticuerpos anti-NGF y su uso |
| EP2606894A1 (en) | 2011-12-20 | 2013-06-26 | Sanofi | Novel therapeutic use of p75 receptor antagonists |
| US9617334B2 (en) | 2012-06-06 | 2017-04-11 | Zoetis Services Llc | Caninized anti-NGF antibodies and methods thereof |
| BR112020017701A2 (pt) | 2018-03-12 | 2020-12-29 | Zoetis Services Llc | Anticorpos anti-ngf e métodos dos mesmos |
| US20230331679A1 (en) * | 2020-07-24 | 2023-10-19 | Jawaharlal Nehru Centre For Advanced Scientific Research | Naphthalene monoimide compounds and methods thereof |
| EP4514998A1 (en) | 2022-04-27 | 2025-03-05 | Regeneron Pharmaceuticals, Inc. | Treatment of arthropathy based upon stratification of osteoarthritis polygenic risk score |
| CN120752534A (zh) | 2023-03-17 | 2025-10-03 | 瑞泽恩制药公司 | 骨关节炎(oa)的蛋白质组学风险评分 |
| WO2026054762A1 (en) | 2024-09-05 | 2026-03-12 | Regeneron Pharmaceuticals, Inc. | Proteomic risk score for adjudicated arthropathy (aa) |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US627129A (en) * | 1899-06-20 | Collar-edge-ironing machine | ||
| US525841A (en) * | 1894-09-11 | Baling-press | ||
| US3821383A (en) * | 1972-07-10 | 1974-06-28 | Ayerst Mckenna & Harrison | Compositions for and a method of treating diabetic complications |
| US4006238A (en) | 1975-08-28 | 1977-02-01 | E. R. Squibb & Sons, Inc. | Use of 2-(hydroxyalkyl)-1H-benz[de]isoquinoline-1,3(2H)-diones as anti-allergy agents |
| ES459497A1 (es) | 1977-06-04 | 1978-04-16 | Made Labor Sa | Un metodo para la preparacion industrial de naftalimidas y sus derivados. |
| US4254109A (en) * | 1979-11-08 | 1981-03-03 | Ayerst, Mckenna & Harrison Inc. | 1H-Benz[de]isoquinoline-2(3H)-acetic acid derivatives |
| RU2051677C1 (ru) * | 1982-02-10 | 1996-01-10 | Украинский научно-исследовательский институт эндокринологии и обмена веществ | Средство для профилактики и лечения диабетических осложнений, ангиопатий, нейропатий, катаракты |
| US5183821A (en) | 1983-09-19 | 1993-02-02 | Laboratories Knoll, S.A. | Method for treating leukemias using N-(2-dimethylaminoethyl)-3-amino-1,8-naphthalimide for treating leukemias and solid tumors |
| IT1214618B (it) * | 1985-06-27 | 1990-01-18 | I P A International Pharmaceut | Composti e composizioni farmaceutiche per la terapia di retinopatie e neuropatie diabetiche. |
| DE3635711A1 (de) | 1986-10-21 | 1988-04-28 | Knoll Ag | 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung |
| DE3707651A1 (de) | 1987-03-10 | 1988-09-22 | Knoll Ag | Bis-naphthalimide, ihre herstellung und verwendung |
| DE3707652A1 (de) * | 1987-03-10 | 1988-09-22 | Knoll Ag | Verwendung von benzo(de)isochinolin-1,3-dionen zur herstellung von arzneimitteln |
| US5420137A (en) | 1989-07-11 | 1995-05-30 | Knoll Ag | Amonafide salts |
| US5356906A (en) * | 1989-10-27 | 1994-10-18 | The Du Pont Merck Pharmaceutical Company | (N-phthalimidoalkyl) piperidines useful as treatments for psychosis |
| CA2030129A1 (en) | 1989-11-29 | 1991-05-30 | Thomas Saupe | 1,8-napthalenedicarboximides as antidotes |
| US5342942A (en) | 1992-06-09 | 1994-08-30 | Warner-Lambert Company | Pyrazoloquinazolone derivatives as neurotrophic agents |
| DE4232739A1 (de) | 1992-09-30 | 1994-03-31 | Knoll Ag | Neue asymmetrisch substituierte bis-Naphthalimide |
| IL110460A (en) | 1993-08-18 | 2001-01-11 | Basf Ag | Bis-naphthalimides, their preparation and pharmaceutical compositions containing them |
| US6291247B1 (en) | 1994-05-11 | 2001-09-18 | Queen's University At Kingston | Methods of screening for factors that disrupt neurotrophin conformation and reduce neurotrophin biological activity |
| GB9616105D0 (en) | 1996-07-31 | 1996-09-11 | Univ Kingston | TrkA binding site of NGF |
| AU728523C (en) | 1996-10-21 | 2001-08-09 | Nps Pharmaceuticals, Inc. | Neurotrophin antagonist compositions |
| ATE383169T1 (de) | 1997-02-07 | 2008-01-15 | Emisphere Tech Inc | Komponente und zusammensetzungen zur verabreichung von wirkstoffen |
| AU7449198A (en) | 1997-05-21 | 1998-12-11 | Japan Tobacco Inc. | Phthalimide derivatives and pharmaceutical containing said derivatives |
| WO2000000472A1 (en) | 1998-06-30 | 2000-01-06 | Du Pont Pharmaceuticals Company | 5-ht7 receptor antagonists |
| WO2000001672A1 (en) | 1998-07-03 | 2000-01-13 | Taiho Pharmaceutical Co., Ltd. | Naphthalimidobenzamide derivatives |
| US6468990B1 (en) | 1999-05-17 | 2002-10-22 | Queen's University At Kingston | Method of inhibiting binding of nerve growth factor to p75 NTR receptor |
| US6492380B1 (en) | 1999-05-17 | 2002-12-10 | Queen's University At Kingston | Method of inhibiting neurotrophin-receptor binding |
-
1997
- 1997-10-20 AU AU46968/97A patent/AU728523C/en not_active Ceased
- 1997-10-20 WO PCT/CA1997/000779 patent/WO1998017278A1/en not_active Ceased
- 1997-10-20 DE DE69735090T patent/DE69735090T2/de not_active Expired - Fee Related
- 1997-10-20 JP JP51875698A patent/JP2001503397A/ja not_active Ceased
- 1997-10-20 IL IL12947597A patent/IL129475A0/xx not_active IP Right Cessation
- 1997-10-20 ES ES97909098T patent/ES2257768T3/es not_active Expired - Lifetime
- 1997-10-20 DK DK97909098T patent/DK0930883T3/da active
- 1997-10-20 EP EP97909098A patent/EP0930883B1/en not_active Expired - Lifetime
- 1997-10-20 NZ NZ335291A patent/NZ335291A/en unknown
- 1997-10-20 CA CA002268450A patent/CA2268450C/en not_active Expired - Fee Related
- 1997-10-20 AT AT97909098T patent/ATE315397T1/de not_active IP Right Cessation
- 1997-10-20 BR BR9712424-9A patent/BR9712424A/pt not_active Application Discontinuation
- 1997-10-20 KR KR1019990703479A patent/KR20000052691A/ko not_active Withdrawn
-
2001
- 2001-01-11 US US09/758,917 patent/US20020169182A1/en not_active Abandoned
-
2005
- 2005-07-13 US US11/179,610 patent/US7291629B2/en not_active Expired - Fee Related
-
2007
- 2007-09-28 US US11/905,406 patent/US20080287484A1/en not_active Abandoned
-
2009
- 2009-04-28 US US12/453,032 patent/US20090215815A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US7291629B2 (en) | 2007-11-06 |
| DE69735090T2 (de) | 2006-09-14 |
| US20020169182A1 (en) | 2002-11-14 |
| IL129475A0 (en) | 2000-02-29 |
| KR20000052691A (ko) | 2000-08-25 |
| WO1998017278A1 (en) | 1998-04-30 |
| US20090215815A1 (en) | 2009-08-27 |
| US20080287484A1 (en) | 2008-11-20 |
| AU728523C (en) | 2001-08-09 |
| JP2001503397A (ja) | 2001-03-13 |
| AU4696897A (en) | 1998-05-15 |
| DK0930883T3 (da) | 2006-05-22 |
| NZ335291A (en) | 2001-02-23 |
| ES2257768T3 (es) | 2006-08-01 |
| CA2268450A1 (en) | 1998-04-30 |
| US20050250807A1 (en) | 2005-11-10 |
| EP0930883A1 (en) | 1999-07-28 |
| DE69735090D1 (de) | 2006-04-06 |
| EP0930883B1 (en) | 2006-01-11 |
| ATE315397T1 (de) | 2006-02-15 |
| AU728523B2 (en) | 2001-01-11 |
| BR9712424A (pt) | 2001-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU728523C (en) | Neurotrophin antagonist compositions | |
| US6492380B1 (en) | Method of inhibiting neurotrophin-receptor binding | |
| US6468990B1 (en) | Method of inhibiting binding of nerve growth factor to p75 NTR receptor | |
| WO2009039635A1 (en) | Methods of modulating neurotrophin-mediated activity | |
| JP2003501418A (ja) | 細胞死を阻害するための組成物および方法 | |
| DE69811492T2 (de) | Benzonaphthyridine | |
| JPWO1997017970A1 (ja) | カイニン酸神経細胞毒性阻害剤及びピリドチアジン誘導体 | |
| US5922875A (en) | Aromatic acid diamides with antigastrin activity, a method for their preparation and their pharmaceutical use | |
| MXPA99003637A (es) | Composiciones antagonistas de las neurotrofinas | |
| US6057334A (en) | Benzo[g]quinoline derivatives | |
| US20040072862A1 (en) | Compositions for treating ischemia-related neuronal damage | |
| AU2005201951B2 (en) | Method of inhibiting neurotrophin-receptor binding | |
| RU2610274C2 (ru) | Производное глутаримидов, его применение, фармацевтическая композиция на его основе, способ его получения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |